Hello. This is the first of many irregular entries I hope to contribute to this blog. I hope that vibrant discussions ensue, with all points of views being put forth and debated. As it happens, this is a cross-post from the CIS blog. The two main points that underlie this post are that: (1) the notion of “harm” should be central to infringement of most forms of IP, as opposed to unauthorized/unpaid gain by someone else, especially if this gain is non-commercial; (2) the idea of public interest should form the crux of the rationale for, and thus limitations upon, IP.
The Confederation of Indian Industry (CII) organized its third annual conference on counterfeiting and piracy, with support from the United States Embassy and the Quality Brands Protection Committee of China (a body comprising more than 80 multinational companies). Last week we criticised the conference in an open letter. This week, we examine a few of the recurring themes that came up at the conference.
Something being substandard is not the same as something being counterfeit.
This was a mistake made by many whenever they invoked ‘counterfeit’ in the sense of something that is violative of one’s patent and trademark rights. The Indian Drugs and Cosmetics Act itself distinguishes between ‘misbranded’, ‘adulterated’, and ‘spurious’ drugs, thus recognizing that something that is made without proper authorization from rights owners isn’t necessarily of a bad quality. Indeed, this was substantiated by an audience member, a lawyer from Dr. Reddy’s Lab. She spoke of a mandi in Agra where they seized medicines being sold under the Dr. Reddy’s name, but produced by local manufacturers. Upon lab testing, it turned out, much to their surprise, that the medicines were of the highest quality and were not substandard. Similarly, many large companies including trusted FMCG companies like Hindustan Unilever and ITC are upbraided by authorities for violations of the Drugs and Cosmetics Act (for the cosmetics they produce) as well as the Prevention of Food Adulteration Act. Thus, even legitimate businesses can produce substandard products. Thus, a product can be unauthorized but not substandard, just as a product can be substandard but not counterfeit.
This distinction becomes very important when we talk about patents, and especially drug patents. Continue reading ‘fallacies, lies, and video pirates’
Recent Comments